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Drug discovery efforts targeting G protein–coupled receptors (GPCRs) have 
succeeded in developing multiple medications for treating various human diseases 
including cancer, metabolic disorders, and inflammatory disorders. These medications 
are broadly classified as either agonists or antagonists that respectively promote or 
inhibit receptor activation by endogenous stimuli. However, there has been a growing 
appreciation that GPCR biased signaling between G protein- and β-arrestin-dependent 
signaling in particular is a promising method for improving drug efficacy and therapy. 
Orexin receptor 1 (OX1R), a member of the GPCRs, is an important drug target in the 
central nervous system. In this study, we identified a novel regulatory phosphorylation 
site (Ser-262) on OX1R that abolished its capability to interact with GRK2, but did 
not affect its interaction with G proteins, GRK5, or β-arrestin1/2 activation, indicating 
that Ser-262 is a key amino acid for OX1R internalization that contributes to 
induction of GRK2-dependent biased signaling via orexin A. Our findings could 
potentially lead to the development of new drug targets for the prevention and 




GPCR: G-protein-coupled receptor, OX1R: Orexin receptor 1, BRET: 
Bioluminescence resonance energy transfer, Ser: Serine, Ala: Alanine, GRK2/5: G 
Protein-coupled receptor kinase 2/5, ELISA: Enzyme linked immunosorbent assay, 
OD: Optical density, Rluc: Renilla reniformis luciferase, EGFP: Enhanced green 
fluorescent protein, LC–MS/MS: Liquid chromatography coupled with tandem mass 

















G protein–coupled receptors (GPCRs), also known as seven-transmembrane 
receptors, are involved in a diverse array of physiological and pathological responses, 
and consequently are common targets of therapeutics [1, 2]. Binding of ligand results 
in activation of GPCR signaling through G proteins and β-arrestins [3]. In canonical 
G protein–dependent signaling, G proteins interact with many effector molecules to 
initiate signaling [4]. Furthermore, the activation of GPCRs mediated by agonist 
recruits and stimulates G Protein-Coupled Receptor Kinases (GRKs). Subsequently, 
the C-terminus or third intracellular loop (ICL3) of GPCRs is phosphorylated on the 
multiple serine or threonine residues, generating high-affinity arrestin-binding sites[5]. 
There is direct interaction between carboxyl-tail of β-arrestin and clathrin-adapter 
protein-2 (AP-2), promoting receptor internalization and intracellular trafficking. In 
addition, β-arrestins mediate β-arrestin dependent signaling[6]. Signaling differences 
between G protein and β-arrestin signaling are the ultimate determinants of 
ligand-specific cell biological effects, and thus may potentially maximize therapeutic 
benefits while minimize adverse effects[7]. Therefore, biased signaling between G 
protein and β-arrestin pathways is a hotspot in the field, and several biased ligands 
and receptors have been identified that signal preferentially, i.e., through either G 
protein– or β-arrestin–mediated pathways [8, 9]. For example, our preliminary study 
revealed that the 348 amino acid in carboxyl-terminal of apelin receptor (APJ), a 
GPCR family member, is required for biased G protein–independent APJ signaling 
mediated by GRKs and β-arrestins [10].  
Orexin/hypocretin receptor 1 (OX1R) is the member of the GPCR rhodopsin 
family, and as such, heterotrimeric G-proteins are the main mediators of signal 
transduction, and β-arrestins are also an equally common interaction partner[11]. 
Many evidences show OX1R is more related to addiction, feeding, reward, emotion 
and motivation [12-14], for example, Gary Aston-Jones et al.[15] found that OX1R 














tegmental area administration of orexin A is sufficient to reinstate previously 
extinguished drug-seeking behavior. Therefore, OX1R was developed as a target for 
novel pharmacotherapeutics, and orexin receptor-targeting molecules have been 
explored, in particular antagonists, such as single orexin-receptor antagonists (SORAs) 
and dual orexin-receptor antagonists (DORAs), to treat some diseases, such as 
addictive disorders and insomnia[16-18]. However, it is still unclear how OX1R 
mediates its G protein and β-dependent signaling pathways.   
In this study, we monitored the ligand-induced phosphorylation sites of OX1R 
and performed mutagenesis to determine their roles, with the goal of precisely 
identifying regulatory phosphorylation sites of OX1R and exploring the effect of 
phosphorylation on signaling. We found that Ser-262 is a key phosphorylation site for 
OX1R, and after Ser-262 was replaced with Ala, orexin A fails to induce GRK2 
recruitment and terminates GRK2-dependent signaling, suggesting that Ser-262 on 















2. Materials and methods 
 
2.1 Plasmid Constructs and Mutagenesis  
The plasmid pcDNA3.1(+)-OX1R was purchased from the Missouri S&T cDNA 
Resource Center. β-arrestin1-Rluc and β-arrestin2-Rluc was generated as described 
previously [19]. Plasmid encoding Golgi-EYFP was kindly provided by Professor 
Katharine Herrick-Davis (Center for Neuropharmacology & Neuroscience and 
Department of Psychiatry, Albany Medical College, USA). AP2u2-mCherry 
(AP2-mCherry) was a gift from Christien Merrifield (Addgene plasmid #27672; 
http://n2t.net/addgene:27672, RRID: Addgene_27672). Overlap extension PCR was 
used to construct OX1R mutants. The high-fidelity Pfu polymerase was used. The 
primers were OX1R: 5’-CCGGAATTCATGGAGCCCTCAGCCACCCCAGG-3’ 
(EcoRI) and 5’-CCGCTCGAGGGGCAGCACTGTGGTGACGCTGGT-3’ (XhoI), or 
OX1R-S262A mutagenic primers: 5’-TGGAAGCGCCCCGCAGACCAGCTGGGG 
-3’ and5’-CCCCAGCTGGTCTGCGGGGCGCTTCCA-3’. After digestion with 
EcoRI and XhoI (Takara, Japan), the mutagenized OX1R cDNA was ligated into 
pcDNA3.1(+) vector. The correct constructs were verified by sequencing (Sangon 
Biotech, Shanghai, China).  
 
2.2 Cells and Transfection 
Human embryonic kidney 293T (HEK293T) cells were cultured in complete 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum at 
37°C, 5% CO2. Transient transfection was performed using Lipofectamine 2000 
(Invitrogen, California, USA). 
 
2.3 Liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) 
After transfection with OX1R for 24h, HEK293T cells were treated with 100 nM 














were extracted and immunoprecipitated with anti-OX1R antibody. The 
immunoprecipitated proteins were then incubated for 2 h with protein A/G 
PLUS–agarose beads. After washing, elution of OX1R complex was performed as 
previously described [10, 20]. The eluted protein samples were subjected to 
SDS-PAGE. The gel was stained with Coomassie at room temperature for 1 h, 
followed by destaining in water. The gel band of the target protein was cut out, 
incubated with 10 mM DTT and 30 mM iodoacetamide, and digested with trypsin 
overnight at 37°C. The complex was analyzed on an Eksigent Nano 1D
 
Plus system 
(Thermo Fisher Scientific, California, USA). Peptides were concentrated and desalted 
on a C18 column (15 cm × 75 µm) and eluted on a Eksigent C18 column (350 µm × 
0.5 mm) at 300 nl/min with the gradient of 5% B for 5 min, 5–40% B for 65 min, 
40–80% B for 66 min, 80% B for 71 min, 80-5% B for 72 min, and 5% B for 90 min 
(solvent A: 0.1% formic acid (v/v); solvent B: 0.1% formic acid (v/v) and 80% 
CH3CN (v/v).  
For database correlation analysis, the Mascot search engine (Matrix Science, 
London, UK) was used to process MS/MS spectra. The phosphorylation and other 
biological modifications were searched. Using trypsin as the enzyme, we searched the 
IPI human database. We manually checked and validated all filtered MS/MS 
spectrums containing potentially phosphorylated peptide. 
 
2.4 Enzyme linked immunosorbent assay (ELISA)  
To investigate the cell-surface expression of wild type (WT) OX1R and mutant 
OX1Rs, HEK293T cells were transiently transfected with HA-WT-OX1R, 
HA-OX1R-S262A, or HA-OX1R-S390A; the same amount of plasmid was used for 
each transfection. After 24 h, cells were subjected to 4% paraformaldehyde fixation at 
room temperature for 15 min. After blocking with 3% BSA for 1 h, primary antibody 
of rabbit polyclonal anti-HA (1:1000) was added and incubated at 4 °C overnight. 
Then, secondary antibody of goat anti-rabbit HRP–conjugated IgG (1:1000) was 
added for incubation at room temperature for 1 h. TMB Plus substrate was used for 














450 nm was detected with a microplate reader (Bio-Rad, USA). Mock transfection 
was set up. The expression level was calculated as: [(ODmutant - ODmock) / (ODwt - 
ODmock)] ×100%. ELISA was carried as described previously [8]. 
 
2.5 Bioluminescence resonance energy transfer (BRET) measurement  
To monitor cell-surface expression of receptor, OX1R-Rluc, OX1R-S262A-Rluc, 
OX1R-S390A-Rluc, or Venus-kras (a plasma membrane–associated BRET acceptor) 
was transiently transfected into HEK293T cells. At 24 h post-transfection, cells were 
trypsinized, plated in a 96-well microplate in HEPES-buffered phenol red-free 
medium (Invitrogen, California, USA), and incubated for 24 h. The coelenterazine h 
(5 μM; Promega, USA) was added. Tristar LB941 plate reader (Berthold Technologies, 
Bad Wildbad, Germany) with an enhanced green fluorescent protein (EGFP) filter 
(500–550 nm) and an Rluc filter (400–475 nm) was used for BRET measurements. To 
analyze the interactions between OX1R and intracellular signaling proteins (GRKs 
and β-arrestins), cells were transfected transiently with Venus/EGFP-tagged receptors 
(WT-OX1R-Venus/EGFP, OX1R-S262A-Venus/EGFP, or OX1R-S390A-Venus/EGFP) 
and Rluc-tagged intracellular signaling proteins (GRK2-Rluc, GRK5-Rluc, 
β-arrestin1-Rluc or β-arrestin2-Rluc) and stimulated with 10
-6
 M orexin A, then we 
measured BRET signals as described above with Tristar LB941 plate reader[21, 22]. 
  
2.6 Total internal reflection fluorescence microscopy (TIRFM) 
A commercial TIRF system (Leica Microsystems) was used. To avoid 
photobleaching, we restricted illumination within a single focal plane. The exposure 
times (three frames/s) were relatively short. The laser power was only 8% at cell 
surface. The evanescent field penetration depth was ~150 nm[23]. 
 
2.7 Co-immunoprecipitation (Co-IP) 
HEK293T cells were co-transfected with Myc-GRK2 and HA-OX1R or 
HA-OX1R-S262A for 48 h. Then, cells were treated with orexin A (100 nM) for 10 














mAb (Sepharose® Bead Conjugate) (Cell Signaling Technology, USA) was added for 
incubation with whole cell lysates at 4°C overnight. The beads were washed five 
times with 500 μl 1× cell lysis buffer. After elution with 20 μl 4× SDS-PAGE sample 
buffer, proteins were analyzed by Western blotting for anti-HA or anti-Myc 
immunoreactivity (Cell Signaling Technology, USA)[10].  
 
2.8 Confocal laser scanning microscopy 
After transfection with WT-OX1R-Venus or OX1R-S262A-Venus and 
mChery-AP2 for 24 h, the cells were stimulated with orexin A (10
-6
 M) for various 
time intervals (0, 15, 30, and 60 min), and fixed as previously described. Laser 
scanning confocal microscope (oil-immersion 40× objective; TSC SP5, Leica, 
Germany) was used for observation. 
 
2.9 Calcium fluorescence measurements  





 cells/well in poly-D-lysine-coated black 96-well plates. After overnight 





 M) at 37 °C, for 30 seconds, and calcium fluorescence was 
detected.  The time-response, the cells were treated for 230 s with 10
-6
 M orexin A at 
37 °C Then, Fluo-4NM Calcium Assay Kit (Invitrogen, California, USA) was used 
for calcium signal detection. Briefly, 100 µl Fluo-4NW working solution was added. 
Cells were cultured for 30 min at 37°C, 5% CO2, and then for an additional 30 min at 
room temperature. Fluorescence was immediately measured on a Tristar LB941 plate 
reader. The calcium ratio was calculated using the formula:  
Calcium fluotescence ratio= (F0- F1)/ F1 
where F0 is the fluorescence value after addition of agonist, and F1 is the fluorescence 
value before addition of agonist. We recorded the peak increase in fluorescence counts. 
The experiment was repeated three times. 
  














luciferase reporter assays  
Cells stably expressing WT-OX1R, OX1R-S262A, or OX1R-S390A were 
co-transfected with pNFAT-Luc or pSEF-Luc (PathDetect, Stratagene). After 24 h, 
cells were treated for 6 h with orexin A (10
-6
 M). Dual-Glo luciferase assay kits 
(Promega, USA) were used to detect relative luminescence units (RLU) for Renilla 
and firefly luciferase, as described previously [24]. 
2.11 Statistical analysis  
GraphPad Prism 5.0 and SPSS 13.0 software were used to analyze results. Data 
were presented as means ± SEM. Comparisons between two groups were analyzed 
with Student’s paired t-test. Multiple group comparisons were conducted by one-way 

















3.1 Identification of phosphorylation sites on OX1R by liquid chromatography 
coupled with tandem mass spectrometry (LC−MS/MS) 
Serine/threoninein the C-terminus or ICL3 of GPCRs are required for receptor 
phosphorylation, internalization, and intracellular trafficking. However, the key 
residues of OX1R are unclear. Putative OX1R phosphorylation site Ser-390 in the 
C-terminal region and Ser-262 in ICL3 were identified using NetPhos 2.0 prediction 
software. Herein, HEK293T cells transfected with OX1Rwere treated with 100 nM 
orexin A for 10 min and then subjected to SDS-PAGE electrophoresis and Coomassie 
Brilliant Blue staining (Fig. 1A). To better identify the specific sites on OX1R that 
were phosphorylated by 100 nM orexin A stimulation, LC−MS/MS was performed. 
Ser-262 in the ICL3 (Fig. 1B) was identified as a phospho-acceptor site, indicating 















Fig 1. Identification of phosphorylation sites on OX1R by LC−MS/MS  
(A) Plasmid OX1R-EGFP was transfected into HEK293T cells and treated with 100 
nM orexin A for the 10 min. Proteins were resolved by SDS-PAGE and stained. Left: 
molecular mass markers; 1 and 2: Co-IP eluent; 3: Co-IP supernatant; 4: whole-cell 
protein (molecular weight of OX1R-EGFP: 75 kDa) (B) Protein was extracted and 
subjected to tryptic digestion, and then analyzed by LC−MS/MS. Ser-262 in ICL3 
was identified as a phosphorylation site on OX1R and the phosphorylated site is 
highlighted in red. 
3.2 Expression and mutation of OX1Rs  














possibility of incorrect OX1R localization, mutated OX1R expression plasmids 
(OX1R-S262A and OX1R-S390A) were first constructed by site-directed mutagenesis 
of Ser to Ala, and then the cell-surface expression level of WT-OX1R, OX1R-S262A, 
and OX1R-S390A in HEK293T cells were investigated by TIRFM, ELISA and BRET. 
HEK293T cells were transfected with WT-OX1R-EGFP, OX1R-S262A-EGFP, 
OX1R-S390A-EGFP, and Golgi-EGFP and observed by TIRFM (488 nm); green 
spots were detected and visualized in cells expressing all OX1R-GFP constructs but 
not Golgi-EGFP (Fig. 2A). In addition, ELISA and BRET revealed no significant 
differences between WT-OX1R, OX1R-S262A, and OX1R-S390A (Fig. 2B and C). 
Three results suggested that compared with WT-OX1R, OX1R mutants had correct 
membrane location and no obvious effect on cell-surface expression of receptor, 
indicating that OX1R mutants were successfully constructed and trafficked to cell 















Fig 2. Cell-surface expression of WT-OX1R, OX1R-S262A, and OX1R-S390A  
(A) Visualization of EGFP-tagged WT-OX1R and mutant OX1Rs on the surface of 
living cells with TIRFM (green particles). Scale bars, 25 μm. (B) Cell surface 
expression of WT-OX1R and mutant OX1Rs, quantified by ELISA. Results are 
expressed as a percentage of cell-surface expression levels of WT-OX1R, after 
correction for nonspecific expression in cells transfected with the empty vector. (C) 
Cell-surface expression of WT-OX1R and mutant OX1Rs, detected by BRET via the 
cell surface marker Kras-Venus and WT-OX1R-Rluc and mutant OX1Rs-Rluc. For 
ELISA and BRET, four independent experiments were performed with triplicate 
samples, and the results are expressed as means±SEM of four experiments. ns, no 














3.3 Ser-262 of OX1R is required for orexin A–induced receptor internalization  
 
3.3.1 Ser-262 Mutation of OX1R impairs its interaction with GRK2, but not with 
GRK5 
GRK2 phosphorylates specific serines and threonines in the C-terminus of 
GPCRs, which leads to the desensitization and internalization of receptors upon 
β-arrestin recruitment. GRK2/5 is localized to the membrane, where it phosphorylates 
agonist-activated GPCRs, which then bind intracellular signaling partners via 
β-arrestin, leading to β-arrestin dependent signaling．Using BRET, we investigated the 
effects of Ser-390 in the C-terminus and Ser-262 in ICL3 on the interaction between 
OX1R and GRK2/5. The BRET assay provides real-time and dynamic insights, 
enabling analyzing protein–protein interactions in living cells. We determined both 
dose- and time-dependent effects of orexin A on the interaction. The dose- and 
time-response curves of GRK2 recruitment to OX1R revealed that the increase of 




 M) in cells 
expressing GRK2-Rluc and WT-OX1R-Venus or OX1R-S390A-Venus. However, the 
mutant OX1R-S262A yielded a significantly lower BRET signal (Fig. 3A). Moreover, 
we observed that BRET signal increased rapidly after 10
-6
 M orexin A treatment in 
cells expressing GRK2-Rluc and WT-OX1R-Venus or OX1R-S390A-Venus, and 
peaked at 10 min. Again, the mutant OX1R-S262A yielded a significantly lower 
BRET signal, which was similar to the negative control (GRK2-Rluc+ Venus) (Fig. 
3B).These results indicate that the efficiency and affinity of OX1R-S262A raised by 
GRK2 was much lower than that of WT-OX1R and OX1R-S390A. In addition, we 
confirmed interaction between OX1R and GRK2 by cellular Co-IP. The interaction 
could be detected following 10
-6
 M orexin A treatment after transfecting with both 
Myc-GRK2 and HA-OX1R, but not either plasmid alone. There was no OX1R and 
GRK2 interaction when expressing both Myc-GRK2 and OX1R-S262A (Fig. 3C). 
By contrast, the dose- and time-response curves of GRK5 recruitment to OX1R 




 M) in 
cells expressing GRK5-Rluc and WT-OX1R-Venus, OX1R-S262A-Venus, or 
















 M orexin A in cells expressing GRK5-Rluc and 
WT-OX1R-Venus, OX1R-S262A-Venus, or OX1R-S390A-Venus, which peaked at 10 
min (Fig. 3E). Critically, the OX1R-Ser-262 to Ala mutation blocked the interaction 
between OX1R and GRK2, indicating that Ser-262 of OX1R was required for orexin 
A–induced recruitment of GRK2 to activated receptors. 
 
Fig 3. Ser-262 mutation of OX1R impairs its interaction with GRK2   
HEK293T cells transiently transfected with Venus-tagged WT-OX1R or 
mutants-OX1R and GRK2-Rluc measured by BRET. (A) Dose-response curve of the 
recruitment of GRK2 to WT-OX1R and mutant OX1Rs, measured by BRET.After 
stimulation with different concentrations of orexin A, BRET signals were recorded 














curve of the recruitment of GRK2 to WT-OX1R and mutant OX1Rs, measured by 
BRET.  BRET signals between receptor and GRK2were recorded every 5 min before 
and after 10
-6 
M orexin-A  stimulation. Four independent experiments were 
performed with triplicate samples, and the results were expressed as means±SEM of 
four experiments. **P<0.01 GRK2-Rluc+WT-OX1R-Venus vs 
GRK2-Rluc+OX1R-S262A-Venus. (C) Interactions between GRK2 and WT-OX1R or 
mutant OX1Rs, measured by Co-IP. HEK293T cells were transfected with both 
HA-OX1R and Myc-GRK2 (co-transfected 1) or with either plasmid alone. The same 
cells were transfected with HA-OX1R-S262A and Myc-GRK2 (co-transfected 2) or 
with either plasmid alone. Samples containing either HA-OX1R or Myc-GRK2 were 
mixed (Mix 1), as were samples containing either HA-OX1R-S262A or Myc-GRK2 
mixed (Mix 2). The results shown are representative images from three independent 
experiments. (D) Dose-response curve of the recruitment of GRK5 to WT-OX1R and 
mutant OX1Rs, measured by BRET. It is the same as the method of measuring GRK2. 
(E) Time-dependent curve of the recruitment of GRK5 to WT-OX1R and mutant 
OX1Rs, measured by BRET.  Four independent experiments were performed with 
triplicate samples, and the results were expressed as means±SEM of four experiments. 
ns, GRK5-Rluc+ WT-OX1R-Venus vs GRK5-Rluc+ OX1R-S262A-Venus.  
 
3.3.2 Ser-262 mutation on OX1R does not affect its interaction with β-arrestin1/2 
To further study OX1R internalization, we used BRET to monitor the effects of 
C-terminal Ser-390 and ICL3 Ser-262 on the interaction between OX1R and 
β-arrestin1/2. The BRET signal following 10
-6
 Morexin A stimulation was detected in 
HEK293T cells expressing β-arrestin1-Rluc and OX1R-S262A-EGFP. β-arrestin 1 
was recruited to OX1R-262A and OX1R-S390A similarly to WT-OX1R. We also 
observed a similar BRET signal after 10
-6
 M orexin A stimulation in HEK293T cells 
expressing β-arrestin2-Rluc and OX1R-S262A-EGFP or WT-OX1R. These results 
indicating that OX1R Ser-262 is important for β-arrestin1/2 binding to OX1R does 
















Fig 4. Ser-262 mutation of OX1R does not alter its interaction with β-arrestin1/2 
Time-dependent curve of recruitment of β-arrestin 1/2 to WT-OX1R and mutant 
OX1Rs, measured by BRET. HEK293T cells transiently transfected with 
EGFP-tagged receptors and β-arrestin1-Rluc (A) or EGFP-tagged OX1R and 
β-arrestin2-Rluc (B), were treated with 10
-6
 M orexin A. BRET signals between 
receptor and β-arrestin1/2 were recorded every 5 min before and after 10 
-6 
M orexin 
A stimulation. Four independent experiments were performed with triplicate samples, 
and the results are expressed as means±SEM of four experiments. ns, 
β-arrestin1/2-Rluc+ WT-OX1R-EGFP vs β-arrestin1/2-Rluc+ OX1R-S262A-EGFP. 
3.3.3 Ser-262 mutation of OX1R impairs its interaction with AP2 














OX1R signaling, HEK293T cells co-expressing WT-OX1R-Venus or 
OX1R-S262A-Venus (shown in green) and mCherry-AP2 (shown in red) were 
stimulated with 10
-6
 M  orexin for various time intervals (0, 15 , 30, and 60 min), 
and the cells were observed under confocal microscope. The results revealed that at 0 
min (before agonist stimulation), there was clear cell surface distribution of OX1R 
(shown in green) and cytosol distribution of mCherry-AP2 (shown in red). After 
orexin A stimulation, there was internalization in HEK293T cells expressing 
WT-OX1R at 15 min. The internalization peaked at 30 min and then, at 60 min, cell 
surface distribution of OX1R was observed. There was co-localization of 
OX1R-Venus (shown in green) and mCherry-AP2 (shown in red) showing as 
moderate yellow fluorescence (Fig. 5A). By contrast, although we confirmed that the 
receptor was expressed, there was no obvious shift in OX1R-S262A-Venus 
localization and no co-localization with mCherry-AP2 after 10
-6
 M orexin A 
stimulation for 60 min (Fig. 5B). The results suggest that mutation of Ser-262 to Ala 
in OX1R can block OX1R internalization and endocytosis induced by orexin A. The 
results showed that the mutation of Ser-262 in OX1R to Ala could reduce the 
















Fig 5. OX1R-S262A mutation impairs agonist-induced receptor internalization and 
endocytosis in HEK293T cells  














OX1R-S262A-Venus (B) and mCherry-AP2, and cells were treated with10
-6
 M orexin 
A for various time intervals (0, 15, 30, and 60 min). Redistribution and co-localization 
(yellow) of receptors (green) and mCherry-AP2 (red) after orexin A stimulation are 
shown. Nuclei were stained with DAPI (blue). The results shown are representative 
images from at least three independent experiments. Scale bars, 10 μm.  
3.4 Ser-262 of OX1R does not alter its interaction with G Proteins  
Upon agonist stimulation, OX1R can be coupled to Gαq and Gα12[25]. Gαq 
activation leads to an increase in the levels of its second messenger (intracellular 
calcium concentration) and its downstream effector, NFAT, whereas Gα12 activation 
leads to an increase in the level of the downstream effector SRF (Fig. 6C). First, we 
dissected the effects of Ser-262 of OX1R on Gαq-dependent signaling by measuring 
intracellular calcium ions (Ca
2+
) using a Tristar LB941 plate reader, and measuring 
NFAT using a double luciferase reporter assay. After stimulation by orexin A, changes 
of Ca
2+
 were detected in cells expressing WT-OX1R, OX1R-S262A, or OX1R-S390A. 
Dose-response curves were generated by nonlinear regression with a wide range 




 M), and the half-maximal effective 
concentration (EC50) values was 10
-6
 M (Fig. 6A). We then monitored changes in the 
ratio over time in the presence of 10
-6
 M orexin A; the results revealed that treatment 
of WT-OX1R cells significantly increased the fluorescence signal. A similar effect 
was also noted in OX1R-S262A/OX1R-S390A cells (Fig. 6B). These results 
suggested that OX1R-Ser-262 did not alter intracellular Ca
2+
 upon agonist stimulation, 
further confirming that Ser-262 cannot affect the activation of Gαq. 
We also evaluated changes of NFAT in cells after stimulation with 10 
-6
 M orexin 
A. Relative to control cells (Mock), the activity of NFAT-luc was significantly higher 
and similar in WT-OX1R, OX1R-S262A and OX1R-S390A cells (Fig. 6D). These 
results imply that Ser-262 cannot alter NFAT activity, which involves the Gαq pathway. 
We further dissected the effects of Ser-262 of OX1R on Gα12-dependent signaling by 
measuring SRF with double luciferase reporter assay. Compared to mock control, the 
activity of SRF-luc was significantly lower and similar in WT-OX1R, OX1R-S262A 
and OX1R-S390A cells (Fig. 6E). These results suggest that Ser-262 cannot alter SRF 
activity, which involves the Gα12 pathway. Collectively, these findings show that 

















Fig 6. Ser-262 mutation of OX1R does not alter its interaction with G Proteins  
(A) HEK293T cells transiently transfected with WT-OX1R or mutant OX1Rs, were 
treated with orexin A. Dose-response curves of intracellular Ca
2+
 for WT-OX1R  and 
mutant OX1Rs at 30 seconds, measured by Fluo-4NM Calcium Assay Kit.. 
Intracellular Ca
2+
 was measured using a Tristar LB941 plate reader. (B) 
Time-dependent curves of intracellular Ca
2+
 for WT-OX1R and mutant OX1Rs, 
measured by Fluo-4NM Calcium Assay Kit. Variations in intracellular calcium 
fluorescence over 230 s with 10 
-6














reader. Four independent experiments were performed with triplicate samples, and the 
results were expressed as the means±SEM of four experiments. ns, WT-OX1R vs 
OX1R-S262A. (C) Schematic of G protein–dependent signaling by OX1R. (D) and (E) 
Effects of WT-OX1R or mutant OX1Rs on NFAT and SRF activities. WT-OX1R, 
OX1R-S262A, OX1R-S390A respectively, twenty-four hours after co-transfection 
with NFAT-RE (D) or SRF-RE (E), the cells were treated with 1000 nM orexin-A 6 
hours before harvest. NFAT and SRF activities were assayed using a Dual-Luciferase 
Reporter Assay System, and ratios of firefly to Renilla luciferase luminescence were 
calculated. Four independent experiments were performed with triplicate samples, and 
the results were expressed as the means±SEM of four experiments. ns, WT-OX1R vs 
OX1R-S262A and OX1R-S390A . 
4. Discussion 
 
GPCRs are the largest class of therapeutic targets in medicine, accounting for 
about a third of marketed drugs [26, 27]. GPCRs interact with a multitude of 
intracellular signaling pathways mediated by G proteins, and desensitization of these 
pathways is mediated by β-arrestins [28]. Signaling of most GPCRs via G proteins is 
terminated by the phosphorylation of active receptors by specific kinases (GRKs) and 
subsequent binding of β-arrestins, which selectively recognize active phosphorylated 
receptors. The interactions between GPCRs and β-arrestins determine the selectivity 
and efficiency of receptor signaling [29, 30]. Our preliminary studies showed that 
most GPCRs can be phosphorylated, and that phosphorylation of GPCRs occurs 
mainly in the C-terminal region or ICL3. Phosphorylation is one of the most 
important ways to regulate the function of GPCRs. Until recently, however, little was 
known about the phosphorylated sites of OX1R. In our study, first, putative OX1R 
phosphorylation site Ser-390 in the C-terminal region and Ser-262 in ICL3 were 
identified using NetPhos 2.0 prediction software. Second, we identified the key 
phosphorylated sites (Ser-262) on OX1R by LC−MS/MS in HEK293T. 
GPCRs are generally of low natural abundance and overexpression is usually a 
prerequisite to their structural or functional characterization. The heterologous 
expression system provides the study of receptor function in well controlled cell 














different cell background. In our study, we used the recombinant cell lines, HEK293T, 
which is widely used cell lines for heterologous expression and the most used cells in 
orexin receptor studies to date. These cells have the advantage of expressing only a 
single orexin receptor subtype, which allows analysis of the receptor subtype 
differences. However, the cell background is very different from the native cells and 
the results may thus not be directly physiologically applicable. 
    β-arrestin inhibit G protein activation and mediate GPCR internalization, and 
may also stimulate β-arrestin signal pathway. OX1R can bind orexin A (also known as 
hypocretin 1) with high affinity, but has considerably less affinity for orexin B (also 
known as hypocretin 2) [31]. Evans et al. have found human OX1R activation attracts 
β-arrestin 1/2 to the membrane in CHO cells, and moves into intracellular puncta with 
the continued presence of orexin A[32]. In our studies, we used orexin A to activate 
OX1R, and examined the roles of OX1R Ser-262 in G-protein and 
β-arrestin-dependent signaling in HEK293T with BRET and confocal microscope.  
We found that OX1R Ser-262 mutation weakened its interaction with GRK2, so that 
OX1R-S262A loses its ability to bind to GRK2, but did not alter its interaction with 
GRK5, β-arrestin1/2, or G-proteins, indicating that after Ser-262 was replaced with 
Ala, orexin A fails to induce GRK2 recruitment and terminates GRK2-dependent 
signaling (Fig. 7). For the G-protein-dependent signaling, OX1R can be coupled to 
Gαq and Gα12 in the presence of orexin A[33]. In our study, we found that Ser-262 
cannot alter intracellular Ca
2+
 and SRF activity, indicating Ser-262 had no effect on G 
protein–dependent signaling  
AP2 is involved in clathrin-dependent endocytosis in which cargo proteins are 
incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) 
which are destined for fusion with the early endosome[34]. The interaction between 
AP2 and OX1R was observed with a confocal microscope. OX1R-S262A-Venus and 
mChery-AP2 were co-transfected into HEK293T cells. It was found that 
OX1R-S262A receptors were evenly distributed cell membrane surface (green) 
without orexin A stimulation (0 min). Then after different orexin A action time, it was 
found that the green fluorescence did not transfer to the cytoplasm, so it could not 
co-localize with the cytoplasm AP2. Therefore, through the above experiments, it is 
concluded that Ser-262 is the key phosphorylation site of OX1R endocytosis, and 
endocytosis will not occur after mutation. Taken together with our results, the 














but had little effect on the activation of G protein coupled with OX1R, and did not 
change the recruitment of GRK5 and β- arrestin. 
   Recently, intense efforts have been made to find signals that can be independently 
activated by agonist-induced receptor conformations or biased ligands, expanding the 
potential for new drugs aimed at these classic targets[35, 36]. Over the past decade, 
biased signaling, in which the activated receptor selectively engages only a subset of 
its potential intracellular partners, has attracted much attention in the GPCR field. 
β-arrestin bias sometimes confers positive effects, whereas G protein bias can cause 
adverse side effects [37, 38]. In this study, we identified a novel regulatory 
phosphorylation site (Ser-262) on OX1R that abolished its capability to interact with 
GRK2 and AP2, but did not affect its interaction with G proteins, GRK5, or 
β-arrestin1/2 activation. These results indicate the existence of biased signal 
transduction, which will benefit future drug development. The biased signal 
transduction may lead to the development of drugs with greater therapeutic potential 
and benefit, and fewer side effects, than current GPCR-targeted drugs for the 
prevention and treatment of insomnia, narcolepsy, and substance abuse. Similar 
conclusions were also arrived at in other studies, for example, G protein-biased ligand 
induces selectively GRK2-dependent signaling [39]. 
It seems that biased signaling could target specific physiological processes. 
However, whether this specificity is mediated by G-protein, β-arrestin, or both 
pathways is unclear, and the clinical ramifications are far from trivial. In the future, it 
will be necessary to investigate the relationship between physiological events and 
specific pathways. In addition, in vivo experiments are needed to further study that 
Ser-262 on OX1R regulates orexin A-induced GRK2 bias signal transduction, which 
















Fig 7. Schematic diagram of G protein–dependent or β-arrestin-dependent signaling 
of WT-OX1R and mutant OX1Rs    
(A) Orexin A binds OX1R and triggers intracellular signaling events, including G 
protein–dependent and β-arrestin-dependent signaling pathways. (B) Orexin A fails to 
elicit GRK2 recruitment and terminates GRK2-dependent signaling when Ser-262 of 
OX1R is replaced with Ala. 
 
Acknowledgements 
This study was funded by the National Nature Science Foundation of Shandong 
Province (ZR2018PC007, ZR2018MC005), the NSFC Cultivation Project of Jining 
Medical University (JYP2018KJ24), and the Science and Technology Innovation 
Foundation for University or College Students of Weifang Medical University 
(KX2019067). 
Author contributions 
Huannan Wang, Zhen Zhang, Rumin Zhang and Chunmei Wang performed the 
experiments; Dexiu Wang, Ruotong Wei, Ruotong Wei and Xiang Gao analyzed the 
data; Xin Cai wrote the manuscript; Jing Chen designed the experiments, wrote and 














version of the manuscript. 
Conflicts of interest 
The authors confirm that there are no conflicts of interest. 
 
References 
[1] Rosenbaum DM, Rasmussen SG, Kobilka BK, Nature. 2009;459:356-363. 
[2] Kobilka BK, Deupi X, Trends Pharmacol. Sci. 2007;28:397-406. 
[3] Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV, Pharmacol. Ther. 
2012;133:40-69. 
[4] McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS, Cell. Mol. Life 
Sci. 2005;62:551-577. 
[5] Chaturvedi M, Maharana J, Shukla AK, Cell. 2020;180:1041-1043. 
[6] Park JY, Lee SY, Kim HR, Seo MD, Chung KY, Arch. Pharm. Res. 
2016;39:293-301. 
[7] Yoo SM, Bhardwaj A, Benovic JL, Trends Pharmacol. Sci. 2020;41:387-389. 
[8] DeWire SM, Violin JD, Circ. Res. 2011;109:205-216. 
[9] Carli M, Kolachalam S, Aringhieri S, Rossi M, Giovannini L, Maggio R, Scarselli 
M, Curr. Neuropharmacol. 2018;16:222-230. 
[10] Chen X, Bai B, Tian Y, Du H, Chen J, J. Biol. Chem. 2014;289:31173-31187. 
[11] Leonard CS, Kukkonen JP, Br. J. Pharmacol. 2014;171:294-313. 
[12] Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, 
Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T, Neuron. 2001;30:345-354. 
[13] Xu TR, Yang Y, Ward R, Gao L, Liu Y, Cell. Signal. 2013;25:2413-2423. 
[14] Sakurai T, Nat. Rev. Neurosci. 2014;15:719-731. 
[15] Bentzley BS, Aston-Jones G, Eur. J. Neurosci. 2015;41:1149-1156. 
[16] Hellmann J, Drabek M, Yin J, Gunera J, Proll T, Kraus F, Langmead CJ, Hubner 
H, Weikert D, Kolb P, Rosenbaum DM, Gmeiner P, Proc. Natl. Acad. Sci. U. S. A. 
2020;117:18059-18067. 















[18] Gentile TA, Simmons SJ, Watson MN, Connelly KL, Brailoiu E, Zhang Y, 
Muschamp JW, Neuropsychopharmacology. 2018;43:1001-1009. 
[19] Chapman NA, Dupre DJ, Rainey JK, Biochem. Cell Biol. 2014;92:431-440. 
[20] Kaneko N, Yoshimori T, Yamamoto R, Capon DJ, Shimada T, Sato TA, Tanaka K, 
Anal. Chem. 2013;85:3152-3159. 
[21] Pfleger KD, Seeber RM, Eidne KA, Nat. Protoc. 2006;1:337-345. 
[22] Bai B, Cai X, Jiang Y, Karteris E, Chen J, J. Cell. Mol. Med. 2014;18:2071-2081. 
[23] Cai X, Bai B, Zhang R, Wang C, Chen J, Sci. Rep. 2017;7:40335. 
[24] Chen J, Zhang R, Chen X, Wang C, Cai X, Liu H, Jiang Y, Liu C, Bai B, Cell. 
Signal. 2015;27:1426-1438. 
[25] Magga J, Bart G, Oker-Blom C, Kukkonen JP, Akerman KE, Nasman J, Biochem. 
Pharmacol. 2006;71:827-836. 
[26] Zhou J, Wild C, Curr. Top. Med. Chem. 2019;19:1363-1364. 
[27] Heifetz A, Schertler GF, Seifert R, Tate CG, Sexton PM, Gurevich VV, Fourmy D, 
Cherezov V, Marshall FH, Storer RI, Moraes I, Tikhonova IG, Tautermann CS, Hunt P, 
Ceska T, Hodgson S, Bodkin MJ, Singh S, Law RJ, Biggin PC, Naunyn 
Schmiedebergs Arch. Pharmacol. 2015;388:883-903. 
[28] Bai B, Jiang Y, Cai X, Chen J, Exp. Cell Res. 2014;328:401-409. 
[29] Gurevich VV, Gurevich EV, Front. Pharmacol. 2019;10:125. 
[30] Harris DM, Cohn HI, Pesant S, Eckhart AD, Clin. Sci. (Lond.). 2008;115:79-89. 
[31] Scammell TE, Winrow CJ, Annu. Rev. Pharmacol. Toxicol. 2011;51:243-266. 
[32] Evans NA, Groarke DA, Warrack J, Greenwood CJ, Dodgson K, Milligan G, 
Wilson S, J. Neurochem. 2001;77:476-485. 
[33] Kukkonen JP, Leonard CS, Br. J. Pharmacol. 2014;171:314-331. 
[34] Motley A, Bright NA, Seaman MN, Robinson MS, J. Cell Biol. 
2003;162:909-918. 
[35] Aude Saulière MB, Hervé Paris, Colette Denis, Frédéric Finana, Jonas T Hansen, 
Marie-Françoise Altié, Marie-Hélène Seguelas, Atul Pathak, Jakob L Hansen, 
Jean-Michel Sénard, Céline Galés, Nat. Chem. Biol. 2012;8:622-630. 














KE, Hunt SW, 3rd, Bouvier M, Proc. Natl. Acad. Sci. U. S. A. 2013;110:E5088-5097. 
[37] Seyedabadi M, Ghahremani MH, Albert PR, Pharmacol. Ther. 
2019;200:148-178. 
[38] Berque-Bestel  LhF, Jockers R., Current drug discovery technologies. 
2008;5:312-318. 



















Huannan Wang, Zhen Zhang, Rumin Zhang and Chunmei Wang performed the 
experiments; Dexiu Wang, Ruotong Wei, Ruotong Wei and Xiang Gao analyzed the 
data; Xin Cai wrote the manuscript; Jing Chen designed the experiments, wrote and 
revised the manuscript. All authors reviewed the results and approved the final 


























A novel regulatory phosphorylation site (Ser-262) on OX1R 
 
OX1R-Ser-262A that abolished its capability to interact with GRK2 
 
No affect its interaction with G proteins, GRK5, or β-arrestin1/2 activation 
 
Ser-262 is a key amino acid for OX1R internalization that contributes to induction of 
GRK2-dependent biased signaling 
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